The Community-based Morbidity of Flexible Cystoscopy
Authors
Affiliations
Objective: To evaluate patients' experience after flexible cystoscopy (FC), particularly concentrating on the prevalence and degree of symptoms, the frequency of visits to their General Practitioner (GP), subsequent antibiotic rates and the actual incidence of urinary tract infection (UTI).
Patients And Methods: Consecutive patients (420) presenting for FC were audited prospectively. A pain score for the procedure was recorded immediately afterward (linear scale 0-10) and a self-administered questionnaire completed at 7 days, to assess the objective and subjective symptoms and their duration, and the incidence of GP visits and subsequent antibiotic provision noted. An interim analysis was conducted on the initial 274 datasets received. To estimate the incidence of FC-induced UTI, the final 110 patients were asked not to consult their GP but to present to the urology department at 3 days after FC (or the emergency department if clinically necessary). These patients had initially provided a mid-stream urine (MSU) sample before FC and were assessed symptomatically with a subsequent sample obtained if a urinary dipstick test 3-days after FC was abnormal.
Results: In all, 384 (91%) evaluable forms were returned. The median (range) pain score for FC was 1.1 (0-8.5), with seven patients (1.8%) recording a pain score of > 5 (all men); 382 patients (99.5%) declared they would be happy to undergo an identical procedure in the future if medically indicated. Pain on voiding was reported in 190 patients (50%), urinary frequency in 142 (37%) and gross haematuria in 73 (19%). Eighteen of the initial 274 patients (6.6%) visited their GP, with 15 (5.5%) of these receiving antibiotics. The MSU data from the final 110 patients showed a FC-mediated infection in three (2.7%).
Conclusion: Although FC is well tolerated, gross haematuria, urinary frequency and dysuria occur afterward much more frequently than expected. Patients should be thoroughly counselled before FC about these potential symptoms, to reduce their concern, any unnecessary GP visits and the use of antibiotics.
Wan X, Wang D, Zhang X, Xu M, Huang Y, Qin W Int J Oncol. 2025; 66(3).
PMID: 39917986 PMC: 11837902. DOI: 10.3892/ijo.2025.5724.
Efficacy and safety of intravesical alkalinized lignocaine for cystoscopy: a retrospective analysis.
Singh K, Das M, Mandal S, Sahoo S, Tarigopula V, Tripathy S Int Urol Nephrol. 2025; .
PMID: 39915424 DOI: 10.1007/s11255-025-04401-9.
Matched serum- and urine-derived biomarkers of interstitial cystitis/bladder pain syndrome.
Kuret T, Sterle I, Romih R, Veranic P PLoS One. 2024; 19(12):e0309815.
PMID: 39739829 PMC: 11687793. DOI: 10.1371/journal.pone.0309815.
Rabien A, Rong D, Rabenhorst S, Schlomm T, Labonte F, Hofbauer S Sci Rep. 2024; 14(1):30617.
PMID: 39715826 PMC: 11666540. DOI: 10.1038/s41598-024-83976-2.
Emerging frontiers of cell-free DNA fragmentomics.
Hu X, Ding S, Jiang P Extracell Vesicles Circ Nucl Acids. 2024; 3(4):380-392.
PMID: 39697357 PMC: 11648524. DOI: 10.20517/evcna.2022.34.